<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neurology</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
      <journal-id journal-id-type="hwp">neurology</journal-id>
      <journal-id journal-id-type="publisher-id">neur</journal-id>
      <journal-id journal-id-type="pmc">neurology</journal-id>
      <journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
      <journal-title-group>
        <journal-title>Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-3878</issn>
      <issn pub-type="epub">1526-632X</issn>
      <publisher>
        <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
        <publisher-loc>Hagerstown, MD</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25636713</article-id>
      <article-id pub-id-type="pmc">4366091</article-id>
      <article-id pub-id-type="publisher-id">NEUROLOGY2014603753</article-id>
      <article-id pub-id-type="doi">10.1212/WNL.0000000000001326</article-id>
      <article-categories>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>14</subject>
          <subject>60</subject>
          <subject>132</subject>
          <subject>236</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Antibodies to GABA<sub>A</sub> receptor &#x3B1;1 and &#x3B3;2 subunits</article-title>
        <subtitle>Clinical and serologic characterization</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pettingill</surname>
            <given-names>Philippa</given-names>
          </name>
          <degrees>DPhil</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>The inventors have unexpectedly identified the &#x3B3; subunit of the GABAA receptor as a novel target in CNS-autoimmunity. Autoantibodies against the &#x3B3; subunit of the GABAA receptor may therefore be used to diagnose or prognose neurological diseases. Accordingly, the invention provides a method of determining whether or not an individual has or is likely to develop a neurological disease, the method comprising detecting the presence or absence of one or more autoantibodies against the &#x3B3;subunit of the &#x3B3;-aminobutyric acid A receptor (GABAAR) in the individual, wherein the presence of one or more autoantibodies indicates that the individual has or is likely to develop the disease and wherein the absence of any autoantibodies indicates that the individual does not have or is not likely to develop the disease</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kramer</surname>
            <given-names>Holger B.</given-names>
          </name>
          <degrees>DPhil</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coebergh</surname>
            <given-names>Jan Adriaan</given-names>
          </name>
          <degrees>MBBS</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>Named on patent for GABA-A antibody assay as other authors</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pettingill</surname>
            <given-names>Rosie</given-names>
          </name>
          <degrees>BSc</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maxwell</surname>
            <given-names>Susan</given-names>
          </name>
          <degrees>BSc</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nibber</surname>
            <given-names>Anjan</given-names>
          </name>
          <degrees>BSc</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Malaspina</surname>
            <given-names>Andrea</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jacob</surname>
            <given-names>Anu</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>Honoraria for speaking on NMO from Biogen Idec and chugai pharmaceuticals</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>Honoraria for speaking on NMO from Biogen Idec and Chugai pharma</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>Biogen grant</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NHS -NMO service NIHR - Strive clinical trial 2014 , United Kingdom</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Irani</surname>
            <given-names>Sarosh R.</given-names>
          </name>
          <degrees>DPhil</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>SRI has received honoraria for speaking at scientific conferences (&lt;1000Euro), including the movement disorder society and Bethel Epilepsy Symposium.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>SRI is a coapplicant and receives royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC-complex antibodies.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>SRI received funding support from by the Fulbright UK-US commission and the MS society (2012-2013).</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>For VGKC-complex antibody patent, as described above. Royalties paid by ISIS Ltd, University of Oxford's IP company in 2012 and 2013.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buckley</surname>
            <given-names>Camilla</given-names>
          </name>
          <degrees>DPhil</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>Medical Research Council Clinician Scientist Fellowship</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beeson</surname>
            <given-names>David</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>Medical Research Council Grant G070152</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>Muscular Dystrophy Campaign Grant RA 722</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lang</surname>
            <given-names>Bethan</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>Charity: member of Medical Committee: Myaware ( ex. myasthenia gravis Association) 2013-</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>1 Use of LGI1 as an antigen in detection of autoantibodies 2. Use of GABAa gamma subunit in detection of autoantibodies (pending)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other activities:</title>
                <list-item>
                  <p>My department receives payment for running Diagnostic assays for a range of autoantibodies</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>Epilepsy research UK (ERUK)P1201 LANG: Established and novel cell-surface autoantibodies in adults with new-onset cryptogenic epilepsies</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>Use of LGI1 as an antigen in detection of autoantibodies (royalties) 2013-2014 ongoing</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Waters</surname>
            <given-names>Patrick</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>Speaker honoraria from Biogen Idec Japan and Euroimmun AG.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>Frontiers in molecular innate immunity, Review editor, 1 yr</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>Assays for the detection of antibodies to lgi1, Caspr2 and tag-1.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>A patent has been submitted on GABAAR.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Vincent</surname>
            <given-names>Angela</given-names>
          </name>
          <degrees>FRCPath</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>Occasional small honoraria travel and a speaker honorarium from Baxter International Inc and Biogen Inc</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>Advisory Editorial Board Neurology Associate Editor for Brain now ended</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>Hold patent with Oxford University for VGKC complex antibodies licensed to Euroimmun AG</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>Royalties from Athena Diagnostics (MuSK assays). Royalties received from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press, 2010)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>Consultancy with Athena Diagnostics for assessing their antibody assays ?5K pa. Now terminated.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>Scientific conference expenses only</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NIHR general support for antibody work</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <aff>From the Nuffield Department of Clinical Neurosciences (P.P., R.P., S.M., A.N., S.R.I., C.B., D.B., B.L., P.W., A.V.) and the Department of Physiology, Anatomy and Genetics (H.B.K.), University of Oxford; St George's Healthcare NHS Trust (J.A.C.), Tooting, London; the Centre for Neuroscience &amp; Trauma, Blizard Institute (A.M.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and The Walton Centre Foundation Trust (A.J.), Liverpool, UK.</aff>
      </contrib-group>
      <author-notes>
        <corresp>Correspondence to Dr. Vincent: <email>angela.vincent@ndcn.ox.ac.uk</email></corresp>
        <fn fn-type="financial-disclosure">
          <p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the authors.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>24</day>
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <volume>84</volume>
      <issue>12</issue>
      <fpage>1233</fpage>
      <lpage>1241</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>11</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 American Academy of Neurology</copyright-statement>
        <copyright-year>2015</copyright-year>
        <copyright-holder>American Academy of Neurology</copyright-holder>
        <license license-type="open-access">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="NEUROLOGY2014603753.pdf"/>
      <abstract>
        <sec>
          <title>Objective:</title>
          <p>To search for antibodies against neuronal cell surface proteins.</p>
        </sec>
        <sec>
          <title>Methods:</title>
          <p>Using immunoprecipitation from neuronal cultures and tandem mass spectrometry, we identified antibodies against the &#x3B1;1 subunit of the &#x3B3;-aminobutyric acid A receptor (GABA<sub>A</sub>R) in a patient whose immunoglobulin G (IgG) antibodies bound to hippocampal neurons. We searched 2,548 sera for antibodies binding to GABA<sub>A</sub>R &#x3B1;, &#x3B2;, and &#x3B3; subunits on live HEK293 cells and identified the class, subclass, and GABA<sub>A</sub>R subunit specificities of the positive samples.</p>
        </sec>
        <sec>
          <title>Results:</title>
          <p>GABA<sub>A</sub>R-Abs were identified in 40 of 2,046 (2%) referred sera previously found negative for neuronal antibodies, in 5/502 (1%) previously positive for other neuronal surface antibodies, but not in 92 healthy individuals. The antibodies in 40% bound to either the &#x3B1;1 (9/45, 20%) or the &#x3B3;2 subunits (9/45, 20%) and were of IgG1 (94%) or IgG3 (6%) subclass. The remaining 60% had lower antibody titers (<italic>p</italic> = 0.0005), which were mainly immunoglobulin M (IgM) (<italic>p</italic> = 0.0025), and showed no defined subunit specificity. Incubation of primary hippocampal neurons with GABA<sub>A</sub>R IgG1 sera reduced surface GABA<sub>A</sub>R membrane expression. The clinical features of 15 patients (GABA<sub>A</sub>R &#x3B1;1 n = 6, &#x3B3;2 n = 5, undefined n = 4) included seizures (47%), memory impairment (47%), hallucinations (33%), or anxiety (20%). Most patients had not been given immunotherapies, but one with new-onset treatment-resistant catatonia made substantial improvement after plasma exchange.</p>
        </sec>
        <sec>
          <title>Conclusions:</title>
          <p>The GABA<sub>A</sub>R &#x3B1;1 and &#x3B3;2 are new targets for antibodies in autoimmune neurologic disease. The full spectrum of clinical features, treatment responses, correlation with antibody specificity, and in particular the role of the IgM antibodies will need to be assessed in future studies.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>special-property</meta-name>
          <meta-value>podcast</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>special-property</meta-name>
          <meta-value>video</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Antibodies directed against proteins expressed in the CNS have been identified in a number of neurologic disorders including various encephalopathies<sup><xref rid="R1" ref-type="bibr">1</xref><xref ref-type="bibr" rid="R2">&#x2013;</xref><xref rid="R3" ref-type="bibr">3</xref></sup> as well as subgroups of patients with epilepsy<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup> or psychiatric disease.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> The antibodies, usually immunoglobulin G (IgG), are directed against extracellular epitopes of proteins expressed on the surface of neuronal cells, including the NMDA receptor (NMDAR), leucine-rich, glioma-inactivated 1 (LGI1), and contactin-associated protein-like 2 (CASPR2), and less frequently against &#x3B3;-aminobutyric acid B receptor (GABA<sub>B</sub>R), &#x3B1;-amino-3-hydroxy-5-methyl-4-isoxazol-propionic acid receptor (AMPAR), or glycine receptors.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> The majority of the patients have a favorable response to immunotherapies<sup><xref rid="R9" ref-type="bibr">9</xref><xref ref-type="bibr" rid="R10">&#x2013;</xref><xref rid="R11" ref-type="bibr">11</xref></sup> and detection of the antibodies in patient sera and CSF have altered diagnosis and management.</p>
    <p>Antibodies to the &#x3B1;1 and &#x3B2;3 subunits of GABA<sub>A</sub>R, 2 subunits of the heteropentameric ligand gated ion channel that mediates the majority of inhibitory neurotransmission in the brain, were recently reported in 18 patients.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> The 6 patients with high serum and CSF GABA<sub>A</sub>R-Abs presented mainly with seizures and refractory status epilepticus, whereas lower serum titers, without CSF antibodies, were observed in 12 patients with broader neurologic diagnoses including stiff-person syndrome and adult-onset opsoclonus myoclonus syndrome.</p>
    <p>We independently identified the GABA<sub>A</sub> &#x3B1;1 subunit and the novel &#x3B3;2 subunit as antibody targets and, using a live cell-based assay, detected them in 45 of a total of 2,548 sera referred for other CNS antibody tests. GABA<sub>A</sub>R-Abs fell into 2 broad groups defined by their subunit specificity, titer, and immunoglobulin class or subclass.</p>
    <sec sec-type="methods" id="s1">
      <title>METHODS</title>
      <sec id="s1-1">
        <title>Standard protocol approvals, registrations, and patient consents.</title>
        <p>The research use of referred sera is approved by the Oxfordshire Research Ethics Committee A (07 Q160X/28). When GABA<sub>A</sub>R was identified, and a cell-based assay (CBA) established, 502 sera with voltage-gated potassium channel (VGKC) complex, NMDAR, or other antibodies, 92 healthy and 112 disease control sera (<xref ref-type="table" rid="T1">table 1</xref>), and a further 2,046 referred sera negative for the requested antibodies were tested for the presence of GABA<sub>A</sub>R-Abs. Brief clinical data were requested from referring neurologists of positive sera. Specific written consent was obtained from patient 2 for inclusion of his case report and videos.</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Summary of serum samples screened for GABA<sub>A</sub>R antibodies</p>
          </caption>
          <graphic xlink:href="NEUROLOGY2014603753TT1"/>
        </table-wrap>
      </sec>
      <sec id="s1-2">
        <title>Immunoprecipitation from cortical neurons.</title>
        <p>To identify new neuronal antibodies, sera were tested for binding to cultured primary rat hippocampal and cortical neurons. A serum with very strong binding was chosen for further study. The patient's IgG was bound to rat cortical neurons, and the immune complexes solubilized with 2% digitonin and captured using Protein G&#x2013;Sepharose beads (Sigma, Dorset, UK). The immunoprecipitate was separated by gel electrophoresis and the GABA<sub>A</sub>R &#x3B1;1 subunit was identified as the target by mass spectroscopy from a sample of digested bands from the patient, but not healthy control, immunoprecipitate.</p>
      </sec>
      <sec id="s1-3">
        <title>Expression of GABA<sub>A</sub>R in transfected human embryonic kidney cells.</title>
        <p>As for other antibody tests,<sup><xref rid="R13" ref-type="bibr">13</xref><xref ref-type="bibr" rid="R14">&#x2013;</xref><xref rid="R15" ref-type="bibr">15</xref></sup> individual GABA<sub>A</sub>R subunits (&#x3B1;1, &#x3B2;2, &#x3B2;3, or &#x3B3;2) were individually or coexpressed in human embryonic kidney 293 (HEK293) T cells and cell surface expression examined (e-Methods, tables e-1 and e-2 on the <italic>Neurology</italic>&#xAE; Web site at <ext-link ext-link-type="uri" xlink:href="http://www.neurology.org/">Neurology.org</ext-link>). Antibody reactivity was initially assessed using HEK293 cells coexpressing &#x3B1;1&#x3B2;2&#x3B3;2 GABA<sub>A</sub>R subunits and binding detected with Alexa Fluor 568 goat antihuman IgG (H + L) (1:750, A-21090, Invitrogen, Paisley, UK). All sera were scored (0: negative, 1: low positive, 2&#x2013;4: positive) and colocalized with a commercial antibody against the &#x3B1;1 subunit of the GABA<sub>A</sub>R (1:500, clone N95/35, Antibodies Inc., Davis, CA). Endpoint dilution titers were established by determining the last dilution at which binding was scored as 1. To determine subunit specificities, all positive sera were tested by CBAs for binding to different GABA<sub>A</sub>R subunit combinations.</p>
        <p>GABA<sub>A</sub>R IgG subclasses were determined by use of subclass-specific mouse antihuman IgG1, IgG2, IgG3, or IgG4 secondary antibodies (The Binding Site, Birmingham, UK), before washing, fixing, and visualization with Alexa Fluor 568 goat antimouse IgG (H + L) (1:750, A-11001, Invitrogen). Immunoglobulin M (IgM)&#x2013;specific antibodies were determined using an Alexa Fluor 488 goat antihuman IgM antibody (1:750, A-2125, Invitrogen).</p>
      </sec>
      <sec id="s1-4">
        <title>Effects of patient antibodies on GABA<sub>A</sub>R expression in vitro.</title>
        <p>Primary P0 rat neuronal cultures (DIV 7) were incubated for 3 days with patient or healthy control serum (1:100; heated at 56&#xB0;C for 30 minutes to inactivate complement). Subsequently, surface proteins were biotinylated, the cells lysed, and biotinylated surface proteins isolated on a NeutrAvidin agarose column (89881, Pierce Biotechnology, Rockford, IL). Isolated membrane proteins were eluted in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) buffer (Invitrogen) containing 50 mM dithiothreitol; equal amounts of samples were then analyzed by SDS-PAGE and Western blot probing for the &#x3B1;1 and &#x3B3;2 subunits of GABA<sub>A</sub>R. Antibody to the transferrin receptor (13-6800, Invitrogen) was used as a cell surface fraction loading control. Quantification of GABA<sub>A</sub>R receptor loss was determined by densitometric analysis of the Western blots using ImageJ software, and calculated as the ratio of &#x3B1;1:transferrin receptor and &#x3B3;2:transferrin receptor.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s2">
      <title>RESULTS</title>
      <sec id="s2-1">
        <title>Identification of GABA<sub>A</sub>R as a target of autoimmunity.</title>
        <p>Patient 1 had a history of neuropsychological changes including elements of obsessive-compulsive disorder and increased anxiety but without psychosis. She was seen by a neurologist but there was no objective evidence of encephalitis and she returned to her care home. Subsequently, serum VGKC complex antibodies were reported (1938 pM), but all other antibody tests (antibodies to LGI1, CASPR2, NMDAR, AMPAR, GABA<sub>B</sub>R, glycine R) were negative. However, her serum IgG bound intensely to the surface of both hippocampal and cortical neuronal cultures, indicating the presence of a potentially pathogenic antibody against a neuronal surface protein (<xref ref-type="fig" rid="F1">figure 1A</xref>). Using immunoprecipitation and mass spectrometry (see Methods), her serum antibodies were found to bind to the &#x3B1;1 subunit of GABA<sub>A</sub>R (figure e-1A). GABA<sub>A</sub>R in the immunoprecipitate from the patient, but not from a healthy individual, was confirmed by Western blotting (<xref ref-type="fig" rid="F1">figure 1B</xref>).</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <title>Identification of the GABA<sub>A</sub> receptor as an antibody target in CNS disease</title>
            <p>(A) The index patient sera showed antibody binding (green) to the surface of live hippocampal neurons that were identified postpermeabilization with the neuronal marker MAP-2 (red). (B) After identification of &#x3B3;-aminobutyric acid A receptor (GABA<sub>A</sub>R) peptides by tandem mass spectroscopy of the immunoprecipitate from cultured neurons, its presence was confirmed by Western blotting using a commercial antibody against the &#x3B1;1 subunit of GABA<sub>A</sub>R (52 kDa); cortical brain homogenate (Cx) was used as positive control. (C) A cell-based assay was developed using human embryonic kidney 293 cells cotransfected the &#x3B1;1, &#x3B2;2, and &#x3B3;2 subunits of GABA<sub>A</sub>R. Antibody binding to GABA<sub>A</sub>R was demonstrated with serum from patient 1 (red), which colocalized with commercial antibody against the &#x3B1;1 subunit (green; upper row). Immunoglobulin G (IgG) immunoreactivity to GABA<sub>A</sub>R was not observed with control serum (lower row). (D) GABA<sub>A</sub>R-Abs were identified in 5/502 sera with known antibodies (3 voltage-gated potassium channel complex, 2 NMDAR-Abs), and 40/2,046 sera previously found negative in other routine antibody tests. Samples scoring above 1 (dotted line) are considered positive. GABA<sub>A</sub>R-Abs were not present in healthy (n = 92) or disease (n = 112) control sera. Scale bars are 30 &#x3BC;m.</p>
          </caption>
          <graphic xlink:href="NEUROLOGY2014603753FF1"/>
        </fig>
      </sec>
      <sec id="s2-2">
        <title>Detection of GABA<sub>A</sub>R-Abs in patient sera.</title>
        <p>In vivo, GABA<sub>A</sub>R is composed of multiple subunits (&#x3B1;1-6, &#x3B2;1-3, &#x3B3;1-3, &#x3C0;, &#x3B5;, &#x3B8;), which combine to form heteropentamers with a central pore; the &#x3B1;1&#x3B2;2&#x3B3;2 is the most abundant neuronal GABA<sub>A</sub>R subtype.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Individual homomeric GABA<sub>A</sub>R subunits and heteropentameric GABA<sub>A</sub>Rs (&#x3B1;1&#x3B2;2&#x3B3;2 subunits) were expressed in HEK cells and their cell surface expression assessed. Immunostaining of permeabilized fixed cells showed intracellular pools of all of the GABA<sub>A</sub>R subunits (figure e-1B), but surface GABA<sub>A</sub>R expression was only found with cotransfection of all 3 GABA<sub>A</sub>R subunits, and we used &#x3B1;1&#x3B2;2&#x3B3;2 to establish the CBA. Patient 1's antibody bound to the surface of live GABA<sub>A</sub>R-transfected cells, colocalizing with commercial GABA<sub>A</sub>R &#x3B1;1 subunit antibody (<xref ref-type="fig" rid="F1">figure 1C</xref>).</p>
      </sec>
      <sec id="s2-3">
        <title>GABA<sub>A</sub>R-Abs in patients and controls.</title>
        <p>Sera from healthy and disease controls (<xref ref-type="table" rid="T1">table 1</xref>) did not bind to GABA<sub>A</sub>R-transfected cells (healthy control mean + 3 SD = 0.28, <xref ref-type="fig" rid="F1">figure 1D</xref>). Only 2 of 108 (1.9%) additional sera positive for VGKC complex antibodies were positive for GABA<sub>A</sub>R-Abs, and adsorption of patient 1's serum showed that GABA<sub>A</sub>R was not a component of the VGKC complex (figure e-2). GABA<sub>A</sub>R &#x3B1;1&#x3B2;2&#x3B3;2 antibodies were detected in only 2 of 393 (0.5%) sera positive for other known neuronal surface antibodies but were present in 40 of 2,046 (2%) sera previously found negative for NMDAR, AMPAR, or GABA<sub>B</sub>R antibodies (<xref ref-type="table" rid="T1">table 1</xref>). Serum endpoint titers were between 1:80 and 1:4,860, and all 45 GABA<sub>A</sub>R-Abs-positive sera bound to live hippocampal neurons (as in <xref ref-type="fig" rid="F1">figure 1A</xref>). There were no CSF samples available for testing from these patients.</p>
      </sec>
      <sec id="s2-4">
        <title>Subunit specificities of GABA<sub>A</sub>R-Abs.</title>
        <p>We tested reactivity to HEK293 cells after substitution of individual subunits (&#x3B1;1&#x3B2;2&#x3B3;2, &#x3B1;2&#x3B2;2&#x3B3;2, &#x3B1;3&#x3B2;2&#x3B3;2, &#x3B1;5&#x3B2;2&#x3B3;2, &#x3B1;1&#x3B2;2&#x3B3;1, &#x3B1;1&#x3B2;3&#x3B3;2, &#x3B1;3&#x3B2;3&#x3B3;2) of the GABA<sub>A</sub>R heteropentamer (for examples, see <xref ref-type="fig" rid="F2">figure 2A</xref>). Replacing the &#x3B1;1 subunit with the &#x3B1;2, &#x3B1;3, or &#x3B1;5 subunits abrogated the binding of serum antibody from 9 patients (20%, including patient 1), demonstrating specificity for the &#x3B1;1 subunit. Replacing &#x3B3;2 with &#x3B3;1 abolished binding in a further 9 sera (20%), indicating &#x3B3;2 antibody specificity. However, neither these substitutions nor replacing &#x3B2;2 with &#x3B2;3 affected binding in the remaining 28 sera. Notably, patients with &#x3B1;1- or &#x3B3;2-specific antibodies had higher antibody titers than patients lacking subunit specificity (Mann-Whitney <italic>p</italic> = 0.0005, <xref ref-type="fig" rid="F2">figure 2B</xref>).</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <title>Specific GABA<sub>A</sub> receptor subunit reactivities and immunoglobulin classes</title>
            <p>(A) In the index patient 1, substitution of the &#x3B1;1 subunit with the &#x3B1;2, &#x3B1;3, or &#x3B1;5 subunit ablated binding to the &#x3B3;-aminobutyric acid A receptor (GABA<sub>A</sub>R)&#x2013;transfected cells, illustrating that the &#x3B1;1 subunit was the antigenic target. &#x3B1;1-Specific antibodies were observed in a further 8 patients (20% of total 45). Case 8 illustrates 1 of 9 sera (20%) that bound only to GABA<sub>A</sub>Rs containing the &#x3B3;2 subunit, but not the &#x3B3;1 subunit (second row). The third row shows sera from patient 15, which bound to all GABA<sub>A</sub>Rs without a defined subunit specificity. (B) Sera with subunit-specific GABA<sub>A</sub>R-Abs (&#x3B1;1 and &#x3B3;2) had significantly higher antibody titers than sera without a distinct subunit reactivity (Mann-Whitney, <italic>p</italic> = 0.0005). (C) Sera with specific &#x3B1;1 (n = 9, red) or &#x3B3;2 subunit (n = 8, blue) antibody reactivities had IgG1 (16) or IgG3 (1) antibodies, compared to only 2/20 sera without a defined GABA<sub>A</sub>R subunit (green) antibody reactivity (both IgG1), <italic>p</italic> &lt; 0.0001, whose antibodies were predominantly immunoglobulin M (IgM), <italic>p</italic> = 0.025 (18/20). IgG = immunoglobulin G.</p>
          </caption>
          <graphic xlink:href="NEUROLOGY2014603753FF2"/>
        </fig>
      </sec>
      <sec id="s2-5">
        <title>IgG class and subclass of GABA<sub>A</sub>R-Abs.</title>
        <p>The antihuman IgG (H + L, A-21090, Invitrogen) is widely used for detection of human IgG binding but as it is directed against total IgG, including both heavy and light chains, it can crossreact with the light chains shared with other classes of antibody. Using anti-IgG or anti-IgM subclass-specific secondary antibodies only 19/37 (51.4%) available sera contained IgG1 (n = 18) or IgG3 (n = 1) GABA<sub>A</sub>R-Abs. Seventeen of the IgG antibodies were specific for GABA<sub>A</sub>R &#x3B1;1 or &#x3B3;2 subunits; 6 of these also had IgM antibodies. By contrast, 18 of the 20 remaining sera, without a defined subunit specificity, were exclusively IgM-GABA<sub>A</sub>R-Abs (<italic>p</italic> = 0.0025, Mann-Whitney; <xref ref-type="fig" rid="F2">figure 2C</xref>).</p>
      </sec>
      <sec id="s2-6">
        <title>GABA<sub>A</sub>R-Abs reduce surface GABA<sub>A</sub>R expression on cultured neurons.</title>
        <p>As patient sera bound to primary cortical neurons, we investigated the effects of 4 sera with high titers (endpoint dilutions 1:540&#x2013;1:4,860) of IgG1 GABA<sub>A</sub>R &#x3B1;1 (n = 2, patients 1 and 2) or &#x3B3;2 subunits (n = 2, patients 8 and 9) on GABA<sub>A</sub>R expression in vitro, as described by others.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> Neuronal cultures were exposed to the heat-inactivated sera (1:100) for 72 hours, and GABA<sub>A</sub>R expression assessed by Western blot. All 4 patient sera caused a reduction in the surface expression of both &#x3B1;1 and &#x3B3;2 subunits when compared to neurons treated with 2 control sera (<italic>p</italic> = 0.0023 and <italic>p</italic> = 0.0067, respectively, <xref ref-type="fig" rid="F3">figure 3, A and B</xref>).</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <title>Patient antibodies reduce GABA<sub>A</sub> receptor surface expression in neuronal cultures</title>
            <p>Primary cortical neuronal cultures (day 7 in vitro) were treated with serum (1:100) from &#x3B3;-aminobutyric acid A receptor patients (n = 4) or healthy controls (n = 2) for 72 hours. (A) Western blot analysis showed that patient serum but not control decreased GABA<sub>A</sub>R levels (&#x3B1;1 [red] and &#x3B3;2 [blue]) on the neuronal surface. &#x3B2;-Transferrin was used as a loading control. (B) Densitometry analysis showed that this loss was significant for both &#x3B1;1 and &#x3B3;2 subunits treated with patient sera relative to healthy control (<italic>p</italic> = 0.0023 and <italic>p</italic> = 0.0067, respectively).</p>
          </caption>
          <graphic xlink:href="NEUROLOGY2014603753FF3"/>
        </fig>
      </sec>
      <sec id="s2-7">
        <title>Clinical features of patients with GABA<sub>A</sub>R-Abs.</title>
        <p>Overall, there were 22 male participants (age 2&#x2013;76 years, median 51) and 23 female participants (age 13&#x2013;80 years, median 54.5). Eight patients (3 M:5 F) were &lt;20 years of age and 9 patients were young adults (21&#x2013;30 years; 5 M:4 F). GABA<sub>A</sub>R-Abs subunit specificity did not correlate with sex (<italic>p</italic> = 0.7631, Fisher exact test) or age (<italic>p</italic> = 0.6444, Mann-Whitney test).</p>
        <p>We subsequently obtained brief clinical data for 15 representative patients, 6 with &#x3B1;1 and 5 with &#x3B3;2 GABA<sub>A</sub>R-Abs specificity, and 4 with undefined subunit specificity (<xref ref-type="table" rid="T2">table 2</xref>). The most common presenting features were seizures (n = 7, 47%), memory impairment (n = 7, 47%) with confusion or disorientation (n = 4, 27%), or psychiatric features (n = 5, 33%) with hallucinations (n = 2, 33%) or anxiety (n = 4, 27%). One 13-year-old girl had a dysembryoplastic neuroepithelial tumor resected earlier in life, with established neurodevelopment problems, but presented with unexplained onset of behavioral disturbance.</p>
        <table-wrap id="T2" position="float">
          <label>Table 2</label>
          <caption>
            <p>Summary of clinical data from 15 patients</p>
          </caption>
          <graphic xlink:href="NEUROLOGY2014603753TT2"/>
        </table-wrap>
        <p>CSF had been examined at presentation in only 4/15 patients; 3/4 were normal. MRIs were normal in 4/9 or not performed (6/15). In the few with informative MRIs, patient 3 (&#x3B1;1-specific antibodies) had unilateral hippocampal high signal but this was thought at the time to be due to temporal lobe seizures rather than autoimmune encephalitis. Patient 10 (&#x3B3;2-specific antibodies), with a small head of caudate on MRI, subsequently was diagnosed with Huntington disease. In 2 other patients there were nonspecific white matter lesions. Patient 14 (subunit undefined) was in remission from non-Hodgkin lymphoma after treatment when she presented with personality changes, memory loss, and confusion. CSF showed lymphocytic pleocytosis and oligoclonal bands, and there was temporal lobe high signal on MRI. The changes were consistent with a paraneoplastic limbic encephalitis rather than direct infiltration. However, there was mediastinal recurrence of the lymphoma and she failed to respond to intrathecal chemotherapy or immunotherapies, dying soon after. At further follow-up (either verbal or at clinic visit, up to 12 months after reporting the antibodies), 4 patients had done well on symptomatic treatment only, and a further 2 appeared to have improved spontaneously. Of the 3 patients who received some immunotherapy, one (patient 2, &#x3B1;1-specific antibodies) clearly improved (see below) and one showed modest improvement but one was declining after a short course. The others were either lost to follow-up or had died (see <xref ref-type="table" rid="T2">table 2</xref>).</p>
      </sec>
      <sec id="s2-8">
        <title>Patient 2 presentation and clinical response to immunotherapy.</title>
        <p>A 17-year-old boy presented to psychiatrists with a 1-month history of forgetfulness and behavioral changes (disturbed thoughts, including harming others, requesting a sex change, paranoid delusions, and attempts to self-harm). He had occasional tachycardia (up to 120 beats/minute) at rest, but neurologic examination and investigation with PET, CSF analysis, MRI, and 2 EEGs had normal results. He displayed intermittent drooling and long periods of staring and verbigeration; at other times he was verbally unresponsive, and sat abnormally still, with grimacing and posturing for more than 1 minute (video 1). He was given a diagnosis of catatonia of unknown etiology and admitted to a psychiatric unit, where he required continuous supervision; His Bush Frances Catatonia Rating Scale (BFCRS) score was 13 (moderate &gt;9, normal 0). He was unresponsive to antidepressant (sertraline, fluoxetine), antipsychotic (olanzapine, haloperidol, quetiapine), and anxiolytic (lorazepam, clonazepam) treatment. He had a Frontal Assessment Battery (FAB) score of 6/18, indicating severe frontal dysfunction. Three months after presentation, GABA<sub>A</sub>R-Abs was detected in his serum (&#x3B1;1-subunit specific; 1:540, IgG1-isotype) and a possible autoimmune etiology was proposed. After consideration of the evidence implicating GABA<sub>A</sub>R in catatonia,<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> the patient received 4 days of plasma exchange (PEX), after which antibodies were no longer detected in his serum and his frontal dysfunction and catatonia resolved within 2 weeks (BFCRS 0, FAB 18/18).</p>
        <p>Six months after PEX, the patient relapsed with bizarre and unpredictable behavior (e.g., sudden onset intense handwashing for a few days followed by new-onset praying) and GABA<sub>A</sub>R-Abs were once again detected in his serum (1:180), but were undetectable in his CSF. There were subtle motor symptoms of catatonia and subtle frontal symptoms (BFCRS 5/FAB 11), and he received PEX again; symptoms of catatonia resolved within 2 weeks. He continued to have reduced verbal fluency, severe apathy, emotional and social withdrawal, blunted affect, and difficulty in abstract thinking (FAB 9/18). He received 5 days of methylprednisolone 1,000 mg IV and 5 days of immunoglobulins in January 2014 and was started on 1 mg/kg/OD prednisolone, which was weaned down to 10 mg/day in August 2014. His FAB returned to 17/18 in April 2014 (video 2). These symptoms improved slowly in the following months but did not disappear, perhaps due to the continued use of olanzapine and fluoxetine and an underlying diagnosis of mild Asperger syndrome made at age 11. His last GABA<sub>A</sub>R-Abs levels in April 2014 were undetectable. At this time his FAB was 17/18. His symptoms of catatonia and frontal dysfunction twice improved, strongly linked to disappearance of GABA<sub>A</sub>R-Abs with immunotherapy.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s3">
      <title>DISCUSSION</title>
      <p>We identified a new antibody target, GABA<sub>A</sub>R, established a CBA using HEK cells expressing heteropentameric GABA<sub>A</sub>Rs, and identified a total of 45 patients with GABA<sub>A</sub>R-Abs. The antibodies in 40% of patients were IgG1 or IgG3, bound to GABA<sub>A</sub>Rs containing &#x3B1;1 or &#x3B3;2 subunits, and all 4 sera tested were able to reduce GABA<sub>A</sub>R expression on live cortical neurons. In the remaining 60%, however, the titers were lower, the antibodies were mainly IgM, and they did not show subunit specificity, although the sera also bound to hippocampal neurons in culture. The clinical features of 15 representative patients included seizures, psychiatric and cognitive problems, and only one had a relevant malignancy. GABA<sub>A</sub>R-Abs are relatively common (up to 2% of referred sera compared with around 4% identified with NMDAR-Abs over the same time period), are potentially pathogenic, and associate with seizure and behavioral phenotypes. However, although the clinical features were variable and the paraclinical findings often normal, one boy with severe catatonia twice improved substantially following immunotherapy in parallel with normalization of his GABA<sub>A</sub>R-Abs.</p>
      <p>GABA<sub>A</sub>Rs are ionotropic cell surface receptors that predominantly mediate the fast-inhibitory neurotransmission in the brain, and are usually assembled as heteropentamers. On activation, influx of chloride ions results in hyperpolarization and stabilization of the neuronal membrane potential. The GABA<sub>A</sub>Rs are the therapeutic target of many clinically important drugs, such as barbiturates, benzodiazepines, and topiramate, with anticonvulsant, anxiolytic, sedative, cognitive, and mood-altering properties (reviewed in <xref rid="R20" ref-type="bibr">reference 20</xref>). In 18 patients, we identified &#x3B1;1 or &#x3B3;2 subunits as the main targets and showed that 4 of these were able to reduce GABA<sub>A</sub>R complexes from the neuronal surface in vitro, most likely through antibody cross-linking and internalization, as described for NMDAR and AMPAR antibodies,<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> supporting the idea that these antibodies are pathogenic.</p>
      <p>This study was initially designed to identify the target for antibodies in a patient with VGKC complex antibody of 1,938 pM. Despite preadsorption of GABA<sub>A</sub>R-Abs, the patient sera still bound to cultured neurons, indicating the presence of a second cell surface neuronal antibody. Thus VGKC complex antibodies that are negative for binding LGI1/CASPR2/Contactin-2 but bind cultured neurons require further study to identify their specific targets and to explore their pathogenicity.</p>
      <p>The sera positive for GABA<sub>A</sub>R-Abs had all been sent for other CNS antibody tests. Although many of the patients had seizures, or cognitive or neuropsychiatric problems, they were given a range of tentative diagnoses (<xref ref-type="table" rid="T2">table 2</xref>). In most there was little to suggest a classical immune-mediated disease such as limbic encephalitis or NMDAR-Abs encephalitis, and in 2 patients a functional or psychogenic condition was suspected initially. Nevertheless, the large number of referrals for CNS autoantibodies (over 6,000 per year from the United Kingdom) and heterogeneity of the patients described here illustrates the increasing interest in identifying antibodies in patients with subacute onset of unexplained seizures or cognitive or psychiatric features.</p>
      <p>GABA<sub>A</sub>R-Abs, binding the &#x3B1;1 or &#x3B2;3 subunits, were identified recently in 6 patients with refractory status epilepticus or epilepsia partialis continua and a change in cognition/behavior with extensive imaging abnormalities<sup><xref rid="R12" ref-type="bibr">12</xref></sup> and in another 12 with a variety of phenotypes and lower titers. The authors did not report &#x3B3;2 subunit specificity or examine the immunoglobulin classes and subclasses. IgG GABA<sub>A</sub> &#x3B2;3 antibodies were also recently reported in 2 patients with thymoma-associated encephalopathies.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Both IgM and IgA NMDAR-Abs have previously been reported to be pathogenic in vitro, but their clinical relevance is not clear<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>; however, the serum GABA<sub>A</sub>R-IgM-Abs identified here, although low titers, were not observed in 92 healthy control sera, and they also bound to live hippocampal neurons. This suggests that they could be pathogenic in vivo if they are able to reach the brain parenchyma, or are synthesized intrathecally. However, these possibilities clearly need further study.</p>
      <p>As this study was retrospective in design, there are several limitations, in particular the lack of available CSF samples and limited or no immunotherapy intervention in all but 2 of the patients. Nevertheless, this study, in suggesting that a potentially pathogenic antibody can associate with clinical features that are less characteristic of the well-known autoimmune encephalitis syndromes, could have implications for the field. Future prospective studies, detecting GABA<sub>A</sub>R-Abs at onset and testing CSF, with judicious use of immunotherapy, and in vitro and in vivo experiments comparing the effects of IgG and IgM antibodies, will be important in determining their clinical relevance.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other">
        <p>Editorial, page <related-article related-article-type="commentary" id="d35e2968" vol="84" page="1192" issue="12" ext-link-type="pmc">1192</related-article></p>
      </fn>
      <fn fn-type="supplementary-material">
        <p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link></p>
      </fn>
    </fn-group>
    <sec sec-type="contributions">
      <title>AUTHOR CONTRIBUTIONS</title>
      <p content-type="contributions">Philippa Pettingill: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients, acquisition of data, statistical analysis. Holger Kramer: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients, acquisition of data. Jan Adriaan Coebergh: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, acquisition of data. Rosemary Pettingill: study concept or design, accepts responsibility for conduct of research and final approval, acquisition of data. Susan Maxwell: analysis or interpretation of data, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients. Anjan Nibber: analysis or interpretation of data, accepts responsibility for conduct of research and final approval, acquisition of data. Andrea Malaspina: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval. Anu Jacob: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval, acquisition of data. Sarosh R. Irani: drafting/revising the manuscript, study concept or design, accepts responsibility for conduct of research and final approval, obtaining funding. Camilla Buckley: drafting/revising the manuscript, study concept or design, accepts responsibility for conduct of research and final approval, study supervision, obtaining funding. David Beeson: study concept or design, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients, study supervision, obtaining funding. Bethan Lang: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients, acquisition of data. Patrick Waters: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients, acquisition of data. Angela Vincent: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, contribution of vital reagents/tools/patients, study supervision, obtaining funding.</p>
    </sec>
    <sec sec-type="funding">
      <title>STUDY FUNDING</title>
      <p content-type="funding">Supported by the <funding-source>Medical Research Council UK</funding-source> (P.P., C.B., D.B.) and the <funding-source>Wellcome Trust OXION Ion Channels Initiative</funding-source> (H.B.K.). Partially supported by the <funding-source>Oxford NIHR Biomedical Research Centre</funding-source> and the <funding-source>National Health Service National Specialised Commissioning Group for Neuromyelitis Optica</funding-source> (P.W., A.V.), <funding-source>Epilepsy Research UK</funding-source> (B.L., S.R.I.), and the <funding-source>BMA Vera Down</funding-source> Grant (S.R.I.).</p>
    </sec>
    <sec sec-type="disclosure">
      <title>DISCLOSURE</title>
      <p content-type="disclosure">P. Pettingill, H. Kramer, J. Coebergh, R. Pettingill, S. Maxwell, A. Nibber, and A. Malaspina report no disclosures relevant to the manuscript. A. Jacob has received honoraria as a speaker on neuromyelitis optica from Biogen Idec and Chugai and is on clinical trial advisory boards for Chugai and Alexion Pharmaceuticals. S. Irani is a coapplicant and receives royalties on patent application WO/2010/046716 titled &#x201C;Neurological autoimmune disorders.&#x201D; The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC complex antibodies. C. Buckley and D. Beeson report no disclosures relevant to the manuscript. P. Waters has received speaker honoraria from Biogen Idec and Euroimmun AG. A. Vincent and the Nuffield Department of Clinical Neurosciences in Oxford receive royalties and payments for antibody assays and A. Vincent is the named inventor on patent application WO/2010/046716 titled &#x201C;Neurological autoimmune disorders.&#x201D; The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC complex antibodies. S.R. Irani, P. Waters, and B. Lang are coinventors and have received royalties. A patent for the detection of GABA<sub>A</sub>&#x3B3;2 receptor antibodies has been filed. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures.</p>
    </sec>
    <glossary>
      <title>GLOSSARY</title>
      <def-list>
        <def-item>
          <term id="G1">AMPAR</term>
          <def>
            <p>&#x3B1;-amino-3-hydroxy-5-methyl-4-isoxazol-propionic acid receptor</p>
          </def>
        </def-item>
        <def-item>
          <term id="G2">BFCRS</term>
          <def>
            <p>Bush Frances Catatonia Rating Scale</p>
          </def>
        </def-item>
        <def-item>
          <term id="G3">CASPR2</term>
          <def>
            <p>contactin-associated protein-like 2</p>
          </def>
        </def-item>
        <def-item>
          <term id="G4">CBA</term>
          <def>
            <p>cell-based assay</p>
          </def>
        </def-item>
        <def-item>
          <term id="G5">FAB</term>
          <def>
            <p>Frontal Assessment Battery</p>
          </def>
        </def-item>
        <def-item>
          <term id="G6">GABA<sub>A</sub>R</term>
          <def>
            <p>&#x3B3;-aminobutyric acid A receptor</p>
          </def>
        </def-item>
        <def-item>
          <term id="G7">HEK293</term>
          <def>
            <p>human embryonic kidney 293</p>
          </def>
        </def-item>
        <def-item>
          <term id="G8">IgG</term>
          <def>
            <p>immunoglobulin G</p>
          </def>
        </def-item>
        <def-item>
          <term id="G9">IgM</term>
          <def>
            <p>immunoglobulin M</p>
          </def>
        </def-item>
        <def-item>
          <term id="G10">LGI1</term>
          <def>
            <p>leucine-rich, glioma-inactivated 1</p>
          </def>
        </def-item>
        <def-item>
          <term id="G11">NMDAR</term>
          <def>
            <p>NMDA receptor</p>
          </def>
        </def-item>
        <def-item>
          <term id="G12">PEX</term>
          <def>
            <p>plasma exchange</p>
          </def>
        </def-item>
        <def-item>
          <term id="G13">SDS-PAGE</term>
          <def>
            <p>sodium dodecyl sulfate polyacrylamide gel electrophoresis</p>
          </def>
        </def-item>
        <def-item>
          <term id="G14">VGKC</term>
          <def>
            <p>voltage-gated potassium channel</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>T&#xFC;z&#xFC;n</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Masjuan</surname><given-names>J</given-names></name></person-group>
<article-title>Paraneoplastic anti&#x2013;N&#x2010;methyl&#x2010;D&#x2010;aspartate receptor encephalitis associated with ovarian teratoma</article-title>. <source>Ann Neurol</source>
<year>2007</year>;<volume>61</volume>:<fpage>25</fpage>&#x2013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">17262855</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location</article-title>. <source>Ann Neurol</source>
<year>2009</year>;<volume>65</volume>:<fpage>424</fpage>&#x2013;<lpage>434</lpage>.<pub-id pub-id-type="pmid">19338055</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>E</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen</article-title>. <source>Lancet Neurol</source>
<year>2010</year>;<volume>9</volume>:<fpage>67</fpage>&#x2013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">19962348</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irani</surname><given-names>S</given-names></name><name><surname>Michell</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>B</given-names></name><name><surname>Pettingill</surname><given-names>P</given-names></name></person-group>
<article-title>Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis</article-title>. <source>Ann Neurol</source>
<year>2011</year>;<volume>69</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21280068</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>T</given-names></name><name><surname>Sills</surname><given-names>GJ</given-names></name><name><surname>Hart</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy</article-title>. <source>Epilepsia</source>
<year>2013</year>;<volume>54</volume>:<fpage>1028</fpage>&#x2013;<lpage>1035</lpage>.<pub-id pub-id-type="pmid">23464826</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Walter</surname><given-names>M</given-names></name><name><surname>Glanz</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis</article-title>. <source>JAMA Psychiatry</source>
<year>2013</year>;<volume>70</volume>:<fpage>271</fpage>&#x2013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">23344076</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsutsui</surname><given-names>K</given-names></name><name><surname>Kanbayashi</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features</article-title>. <source>BMC Psychiatry</source>
<year>2012</year>;<volume>12</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">22569157</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Bien</surname><given-names>CG</given-names></name><name><surname>Irani</surname><given-names>SR</given-names></name><name><surname>Waters</surname><given-names>P</given-names></name></person-group>
<article-title>Autoantibodies associated with diseases of the CNS: new developments and future challenges</article-title>. <source>Lancet Neurol</source>
<year>2011</year>;<volume>10</volume>:<fpage>759</fpage>&#x2013;<lpage>772</lpage>.<pub-id pub-id-type="pmid">21777830</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Buckley</surname><given-names>C</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis</article-title>. <source>Brain</source>
<year>2004</year>;<volume>127</volume>:<fpage>701</fpage>&#x2013;<lpage>712</lpage>.<pub-id pub-id-type="pmid">14960497</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Gleichman</surname><given-names>AJ</given-names></name><name><surname>Hughes</surname><given-names>EG</given-names></name><etal/></person-group>
<article-title>Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</article-title>. <source>Lancet Neurol</source>
<year>2008</year>;<volume>7</volume>:<fpage>1091</fpage>&#x2013;<lpage>1098</lpage>.<pub-id pub-id-type="pmid">18851928</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titulaer</surname><given-names>MJ</given-names></name><name><surname>McCracken</surname><given-names>L</given-names></name><name><surname>Gabilondo</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study</article-title>. <source>Lancet Neurol</source>
<year>2013</year>;<volume>12</volume>:<fpage>157</fpage>&#x2013;<lpage>165</lpage>.<pub-id pub-id-type="pmid">23290630</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit-Pedrol</surname><given-names>M</given-names></name><name><surname>Armangue</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies</article-title>. <source>Lancet Neurol</source>
<year>2014</year>;<volume>13</volume>:<fpage>276</fpage>&#x2013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">24462240</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>MI</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Viegas</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>IgG1 antibodies to acetylcholine receptors in &#x201C;seronegative&#x201D; myasthenia gravis</article-title>. <source>Brain</source>
<year>2008</year>;<volume>131</volume>:<fpage>1940</fpage>&#x2013;<lpage>1952</lpage>.<pub-id pub-id-type="pmid">18515870</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>P</given-names></name><name><surname>Jarius</surname><given-names>S</given-names></name><name><surname>Littleton</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis</article-title>. <source>Arch Neurol</source>
<year>2008</year>;<volume>65</volume>:<fpage>913</fpage>&#x2013;<lpage>919</lpage>.<pub-id pub-id-type="pmid">18625857</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irani</surname><given-names>SR</given-names></name><name><surname>Alexander</surname><given-names>S</given-names></name><name><surname>Waters</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia</article-title>. <source>Brain</source>
<year>2010</year>;<volume>133</volume>:<fpage>2734</fpage>&#x2013;<lpage>2748</lpage>.<pub-id pub-id-type="pmid">20663977</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirker</surname><given-names>S</given-names></name><name><surname>Schwarzer</surname><given-names>C</given-names></name><name><surname>Wieselthaler</surname><given-names>A</given-names></name><name><surname>Sieghart</surname><given-names>W</given-names></name><name><surname>Sperk</surname><given-names>G</given-names></name></person-group>
<article-title>GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain</article-title>. <source>Neuroscience</source>
<year>2000</year>;<volume>101</volume>:<fpage>815</fpage>&#x2013;<lpage>850</lpage>.<pub-id pub-id-type="pmid">11113332</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Gleichman</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis</article-title>. <source>J Neurosci</source>
<year>2010</year>;<volume>30</volume>:<fpage>5866</fpage>&#x2013;<lpage>5875</lpage>.<pub-id pub-id-type="pmid">20427647</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northoff</surname><given-names>G</given-names></name><name><surname>Steinke</surname><given-names>R</given-names></name><name><surname>Czcervenka</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>1999</year>;<volume>67</volume>:<fpage>445</fpage>&#x2013;<lpage>450</lpage>.<pub-id pub-id-type="pmid">10486389</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiebking</surname><given-names>C</given-names></name><name><surname>Duncan</surname><given-names>NW</given-names></name><name><surname>Qin</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>External awareness and GABA: a multimodal imaging study combining fMRI and [18F]flumazenil-PET</article-title>. <source>Hum Brain Mapp</source>
<year>2014</year>;<volume>35</volume>:<fpage>173</fpage>&#x2013;<lpage>184</lpage>.<pub-id pub-id-type="pmid">22996793</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>MA</given-names></name><name><surname>L&#xF6;scher</surname><given-names>W</given-names></name></person-group>
<article-title>The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions</article-title>. <source>Nat Med</source>
<year>2004</year>;<volume>10</volume>:<fpage>685</fpage>&#x2013;<lpage>692</lpage>
<comment>Review</comment>.<pub-id pub-id-type="pmid">15229516</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkawa</surname><given-names>T</given-names></name><name><surname>Satake</surname><given-names>S</given-names></name><name><surname>Yokoi</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis</article-title>. <source>J Neurosci</source>
<year>2014</year>;<volume>34</volume>:<fpage>8151</fpage>&#x2013;<lpage>8163</lpage>.<pub-id pub-id-type="pmid">24920620</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pr&#xFC;ss</surname><given-names>H</given-names></name><name><surname>Finke</surname><given-names>C</given-names></name><name><surname>H&#xF6;ltje</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis</article-title>. <source>Ann Neurol</source>
<year>2012</year>;<volume>72</volume>:<fpage>902</fpage>&#x2013;<lpage>911</lpage>.<pub-id pub-id-type="pmid">23280840</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pr&#xFC;ss</surname><given-names>H</given-names></name><name><surname>H&#xF6;ltje</surname><given-names>M</given-names></name><name><surname>Maier</surname><given-names>N</given-names></name><name><surname>Gomez</surname><given-names>A</given-names></name><name><surname>Buchert</surname><given-names>R</given-names></name></person-group>
<article-title>IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>78</volume>:<fpage>1743</fpage>&#x2013;<lpage>1753</lpage>.<pub-id pub-id-type="pmid">22539565</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
